5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from anxiety.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from psychomotor retardation.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from cognitive dysfunction.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a mental or nervous system disorder in a mother having a child of age 18 months or below.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from sleep disturbance.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from social/emotional withdrawal or detachment, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt a thereof is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from postpartum depression (PPD).
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from sleep disturbance, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from anxiety, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from psychomotor retardation, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intra-venous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from negative thinking, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is diagnosed with bipolar disorder, wherein the 5-MeO-DMT is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is diagnosed with bipolar disorder.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from cognitive dysfunction, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from negative thinking.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from social/emotional withdrawal or detachment.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from postpartum depression (PPD) wherein the 5-MeO-DMT is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a mental or nervous system disorder in a mother having a child of age 18 months or below, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
Provided are compositions for use in treating a patient suffering from a mental disorder in particular major depressive disorder, persistent depressive disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder and psychoactive substance abuse. Further provided are dosing regimens for treating these disorders.
A system for delivering an aerosolized drug to a patient. The system includes a holding chamber (108), suitable to contain a drug to be aerosolized, and a connect element (100) having first and second ends, the second end being opposite to the first end and being suitable to be connected to the holding chamber (108). The connect element further comprises one or more mating mechanism (102, 104, 112, 114, 118) proximal its first end. The system can also include a mouthpiece (400), a drug assembly (200) including a drug housing (216) and a drug cartridge (300), and a vaporizer (500).
A61M 11/04 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux agissant par pression de la vapeur des liquides à pulvériser ou vaporiser
A method for preparing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is provided which starts from 5-methoxy-1H-indole. The product obtained can be purified via formation of a salt, such as a fumarate salt, of 5-MeO-DMT.
Method of treating a patient who is diagnosed with major depressive disorder by a licensed professional in accordance with accepted medical practice, that includes administering to the patient who is diagnosed with major depressive disorder by a licensed professional in accordance with accepted medical practice a therapeutically effective amount of 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from postpartum depression (PPD).
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a mental or nervous system disorder in a mother having a child of age 18 months or below.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a mental or nervous system disorder in a mother having a child of age 18 months or below, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from postpartum depression (PPD) wherein the 5-MeO-DMT is administered via the intravenous, intramuscular or subcutaneous route.
A drug pad is operable to retain a drug. The drug pad includes a plurality of sintered metal fibers forming a plurality of pores, and a drug retained on the plurality of sintered metal fibers. The plurality of pores define a porosity of the drug pad.
A61M 11/04 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux agissant par pression de la vapeur des liquides à pulvériser ou vaporiser
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from postpartum depression (PPD) wherein the 5-MeO-DMT is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a mental or nervous system disorder in a mother having a child of age 18 months or below, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from postpartum depression (PPD).
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a mental or nervous system disorder in a mother having a child of age 18 months or below.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from sleep disturbance.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from sleep disturbance, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is diagnosed with bipolar disorder.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from anxiety.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from cognitive dysfunction.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from postpartum depression (PPD).
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from social/emotional withdrawal or detachment.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a mental or nervous system disorder in a mother hav- ing a child of age 18 months or below.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a mental or nervous system disorder in a mother having a child of age 18 months or below, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is diagnosed with bipolar disorder, wherein the 5-MeO-DMT is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from negative thinking.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from negative thinking, wherein the 5-MeO- DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from cognitive dysfunction, wherein the 5- MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intrave- nous, intramuscular or subcutaneous route.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
48.
5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF POSTPARTUM DEPRESSION
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from postpartum depression (PPD) wherein the 5-MeO-DMT is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from anxiety, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from psychomotor retardation.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from psychomotor retardation, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intra-venous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from social/emotional withdrawal or detachment, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
Aerosols of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof are provided which are useful for administration to a patient through an inhalation route. The aerosols have aerosol particle mass densities in the range of about 0.5 mg/l to about 12.5 mg/l.
A method for preparing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is provided which starts from 5-methoxy-1H-indole. The product obtained can be purified via formation of a salt, such as a fumarate salt, of 5-MeO-DMT.
A method of purifying 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is provided which comprises dissolving crude 5-MeO-DMT in a solvent at a temperature above room temperature, cooling the obtained solution to a temperature below room temperature to precipitate solid 5-MeO-DMT, separating the solid 5-MeO-DMT from the remaining solution and removing solvent from the crystalline 5-MeO-DMT. In the method, the solvent comprises one or more ethers and less than 5 wt % anti-solvent.
A method of purifying 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is provided which comprises dissolving crude 5-MeO-DMT in a solvent at a temperature above room temperature, cooling the obtained solution to a temperature below room temperature to precipitate solid 5-MeO- DMT, separating the solid 5-MeO-DMT from the remaining solution and removing solvent from the crystalline 5-MeO-DMT. In the method, the solvent comprises one or more ethers and less than 5 wt% anti-solvent.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from postpartum depression (PPD).
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from cognitive dysfunction.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is diagnosed with bipolar disorder, wherein the 5-MeO-DMT is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a mental or nervous system disorder in a mother having a child of age 18 months or below, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from postpartum depression (PPD) wherein the 5-MeO-DMT is administered via the intravenous, intramuscular or subcutaneous route.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from social/emotional withdrawal or detachment, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
Aerosols of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof are provided which are useful for administration to a patient through an inhalation route. The aerosols have aerosol particle mass densities in the range of about 0.5 mg/I to about 12.5 mg/I.
Provided are compositions comprising 5-Methoxy-N,N- dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in treating major depressive disorder, wherein the 5-MeO-DMT is administered via the intravenous, intramuscular or subcutaneous route. Further provided are dosing regimens for treating this disorder.
Provided are compositions for use in treating a patient suffering from a mental disorder in particular major depressive disorder, persistent depressive disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder and psychoactive substance abuse. Further provided are dosing regimens for treating these disorders.
A method for preparing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is provided which starts from 5-methoxy-1H-indole. The product obtained can be purified via formation of a salt, such as a fumarate salt, of 5-MeO-DMT.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
73.
5-METHOXY-N.N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF PSYCHOMOTOR RETARDATION
A61M 11/04 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux agissant par pression de la vapeur des liquides à pulvériser ou vaporiser
brevets
